招银国际研究报告指，药明合联(02268.HK) 发盈喜，料2025年收入将按年增长至少45%，净利润增长逾38%。而经调整净利润预计增长逾45%；若剔除外汇影响，增幅达65%以上。2025年，公司新综合项目破纪录达70个，按年增长32%。工艺性能项目(PPQ)按年飙升125%至18个，显示商业化生产潜力强劲。为应对日益增长的客户需求，公司宣布以现金要约方式收购东曜药业(01875.HK) 至少...
Source Link招银国际研究报告指，药明合联(02268.HK) 发盈喜，料2025年收入将按年增长至少45%，净利润增长逾38%。而经调整净利润预计增长逾45%；若剔除外汇影响，增幅达65%以上。2025年，公司新综合项目破纪录达70个，按年增长32%。工艺性能项目(PPQ)按年飙升125%至18个，显示商业化生产潜力强劲。为应对日益增长的客户需求，公司宣布以现金要约方式收购东曜药业(01875.HK) 至少...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.